Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

VERV

Verve Therapeutics Inc

May 13 • 04:00PM ET

6.22

Dollar change +0.21
Percentage change 3.49	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VB ARKG ARKK VBK VXF IWM IWN VTWO VHT

Index	RUT	P/E	-	EPS (ttm)	-2.88	Insider Own	30.24%	Shs Outstand	81.97M	Perf Week	-2.96%
Market Cap	488.58M	Forward P/E	-	EPS next Y	-2.85	Insider Trans	-0.01%	Shs Float	54.79M	Perf Month	-18.16%
Income	-196.83M	PEG	-	EPS next Q	-0.66	Inst Own	75.03%	Short Float	30.19%	Perf Quarter	-53.69%
Sales	16.05M	P/S	30.44	EPS this Y	17.60%	Inst Trans	24.11%	Short Ratio	12.43	Perf Half Y	-61.22%
Book/sh	6.96	P/B	0.89	EPS next Y	-10.82%	ROA	-28.80%	Short Interest	16.54M	Perf Year	-65.73%
Cash/sh	7.72	P/C	0.81	EPS next 5Y	-	ROE	-36.03%	52W Range	5.84 - 21.42	Perf YTD	-55.38%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-67.06%	ROI	-30.44%	52W High	-70.96%	Beta	1.93
Dividend TTM	-	Quick Ratio	19.82	Sales past 5Y	126.44%	Gross Margin	41.59%	52W Low	6.51%	ATR (14)	0.61
Dividend Ex-Date	-	Current Ratio	19.82	EPS Y/Y TTM	8.45%	Oper. Margin	-1381.45%	RSI (14)	33.74	Volatility	8.60% 7.49%
Employees	255	Debt/Eq	0.13	Sales Y/Y TTM	379.79%	Profit Margin	-1226.43%	Recom	1.36	Target Price	26.89
Option/Short	Yes / Yes	LT Debt/Eq	0.11	EPS Q/Q	30.31%	Payout	-	Rel Volume	1.29	Prev Close	6.01
Sales Surprise	170.39%	EPS Surprise	15.89%	Sales Q/Q	305.63%	Earnings	May 08 BMO	Avg Volume	1.33M	Price	6.22
SMA20	-3.63%	SMA50	-37.50%	SMA200	-49.89%	Trades		Volume	1,711,859	Change	3.49%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-08-24	Initiated	H.C. Wainwright	Buy	$15
Apr-13-23	Initiated	Canaccord Genuity	Buy	$29
Feb-01-23	Initiated	Cantor Fitzgerald	Neutral	$21
Dec-15-22	Initiated	Goldman	Sell	$13
Oct-06-22	Initiated	Credit Suisse	Neutral	$48
Aug-25-22	Upgrade	Stifel	Hold → Buy	$32 → $56
Jun-17-22	Initiated	BMO Capital Markets	Outperform	$48
Feb-18-22	Initiated	RBC Capital Mkts	Outperform	$42
Sep-24-21	Initiated	Stifel	Hold	$58
Jul-12-21	Initiated	William Blair	Outperform	$92
Jul-12-21	Initiated	JP Morgan	Neutral	$50
Jul-12-21	Initiated	Jefferies	Buy	$72
Jul-12-21	Initiated	Guggenheim	Buy	$84

Show Previous Ratings

May-12-24 04:00PM	3 Underappreciated Stocks That Could 10x in 10 Years (InvestorPlace)
May-08-24 01:54PM	VERV Stock Earnings: Verve Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:10AM	Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:10AM	Verve Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results (GlobeNewswire)
07:20AM	Loading…
May-07-24 07:20AM	Verve moves forward with backup base editing therapy (BioPharma Dive)
07:00AM	Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102 (GlobeNewswire)
May-03-24 04:01PM	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-19-24 10:30AM	Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Verve Therapeutics, Inc. for potential violations of federal securities laws (PR Newswire)
Apr-06-24 09:50AM	After a Serious Setback, Is Verve Therapeutics a Buy? (Motley Fool)
Apr-03-24 01:40PM	Verve (VERV) Pauses Enrollment in Cholesterol Study, Stock Falls (Zacks)
Apr-02-24 04:04PM	Verve Plunges To Record Low After Cholesterol-Lowering Gene Editor Causes Side Effects (Investor's Business Daily) -34.95%
10:36AM	Verve Plunges To Record High After Cholesterol-Lowering Gene Editor Causes Side Effects (Investor's Business Daily)
09:31AM	Verve Falls as Gene-Editing Trial Paused on Safety Issues (Bloomberg)
09:01AM	Verve Plummets To Record Low After Its Gene-Editing Drug Causes Side Effects (Investor's Business Daily)
07:35AM	Loading…
07:35AM	UPDATE 1-Verve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levels (Reuters)
07:00AM	Verve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levels (Reuters)
07:00AM	Verve Therapeutics Announces Updates on its PCSK9 Program (GlobeNewswire)
03:03AM	Verve pauses base editing trial, shifts strategy after treatment side effect (BioPharma Dive)
Mar-28-24 04:51PM	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-21-24 04:19PM	3 Stocks That Could Be the Next Big Thing in Gene Editing (InvestorPlace)
Mar-01-24 04:01PM	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-27-24 07:02PM	Verve Therapeutics Inc (VERV) Reports Progress and Financials for Q4 and Full Year 2023 (GuruFocus.com) +21.47%
08:03AM	Verve Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-19-24 04:08PM	3 Biotech Stocks to Buy That Have CRISPR-Like Breakthrough Potential (InvestorPlace)
Feb-13-24 06:05AM	3 Gene Editing Stocks With Unprecedented Surge Potential (InvestorPlace) -9.23%
Feb-12-24 08:30AM	2 Risky Gene-Editing Stocks to Buy in the New Bull Market if You Dare (Motley Fool) +8.31%
Feb-01-24 06:30AM	Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-31-24 12:28PM	3 Once-in-a-Lifetime Gene Editing Stocks with Unprecedented Surge Potential (InvestorPlace)
12:04PM	Loading…
Jan-17-24 12:04PM	7 Mighty Healthcare Stocks Changing the Game of Medicine (InvestorPlace)
Jan-11-24 04:38PM	3 Stocks to Buy in the Booming Field of Gene Editing (InvestorPlace) -5.66%
Jan-04-24 08:00AM	Analysts Agree These 8 Cathie Wood Stock Picks Will Soar In 2024 (Investor's Business Daily)
Jan-02-24 06:30AM	Verve Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-29-23 12:00PM	Verve Therapeutics (VERV) Moves to Buy: Rationale Behind the Upgrade (Zacks) -6.76%
09:55AM	Wall Street Analysts Think Verve Therapeutics (VERV) Could Surge 217.73%: Read This Before Placing a Bet (Zacks)
Dec-13-23 09:55AM	Wall Street Analysts Believe Verve Therapeutics (VERV) Could Rally 260.31%: Here's is How to Trade (Zacks) +9.82%
Dec-06-23 12:31PM	Hedge Fund and Insider Trading News: Palliser Capital, Balyasny Asset Management , Millennium Management, Blackwells Capital, Pantera Capital, NCR Voyix Corp (VYX), Verve Therapeutics, Inc. (VERV), and More (Insider Monkey) +7.95%
Dec-01-23 04:00PM	Verve Therapeutics Announces Closing of Public Offering of Common Stock, Full Exercise by Underwriters of Option to Purchase Additional Shares and Closing of Concurrent Private Placement (GlobeNewswire)
Nov-28-23 10:37PM	Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement (GlobeNewswire)
04:01PM	Verve Therapeutics Announces Proposed Public Offering of Common Stock and Concurrent Private Placement (GlobeNewswire)
Nov-27-23 09:55AM	Does Verve Therapeutics (VERV) Have the Potential to Rally 260.31% as Wall Street Analysts Expect? (Zacks)
Nov-20-23 04:26PM	Verve Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses (GlobeNewswire) +5.37%
Nov-17-23 03:41PM	Why Verve Therapeutics Stock Crashed as Much as 30% This Week (Motley Fool) +6.83%
Nov-16-23 05:41AM	Verve Therapeutics: Why Great Results Aren't Enough (Motley Fool)
05:20AM	After Its Stock Crashed 42% in 1 Day, Is Verve Therapeutics a Buy? (Motley Fool)
Nov-13-23 07:20PM	Heart Disease Breakthrough by Gene-Editor Verve Knocks Its Stock for a Loop (Barrons.com) -40.83%
04:03PM	Verve Loses A Third Of Its Value As Safety Concerns Plague Its Gene-Editing Drug (Investor's Business Daily)
02:28PM	Rebel's Edge - November 13: $BA, $VERV, $MNDY, and Harbaugh Stealing Signs (TheStreet.com)
12:17PM	Verve Therapeutics, Immersion fall; Tower Semiconductor, Boeing rise, Monday, 11/13/2023 (Associated Press Finance)
12:07PM	These 2 Stocks Are Making Big Monday Moves (Motley Fool)
08:56AM	Why Is Verve Therapeutics (VERV) Stock Down 39% Today? (InvestorPlace)
Nov-12-23 03:30PM	Verve Therapeutics Announces Interim Data for VERVE-101 Demonstrating First Human Proof-of-Concept for In Vivo Base Editing with Dose-Dependent Reductions in LDL-C and Blood PCSK9 Protein in Patients with Heterozygous Familial Hypercholesterolemia (GlobeNewswire)
10:34AM	First look at Verve study data offer base editing proof of principle (BioPharma Dive)
Nov-09-23 09:55AM	Wall Street Analysts Predict a 160.72% Upside in Verve Therapeutics (VERV): Here's What You Should Know (Zacks)
08:00AM	1 Cathie Wood Stock to Buy Hand Over Fist Right Now (Motley Fool)
05:57AM	2 Growth Stocks That Already Jumped 50% in November and Could Keep Climbing Higher (Motley Fool)
Nov-07-23 07:56AM	Verve Therapeutics Inc (VERV) Reports Q3 2023 Financial Results (GuruFocus.com) +24.83%
06:36AM	Verve Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
06:30AM	Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-06-23 08:02AM	Cathie Wood's ARK Innovation Just Had Its Best Week Ever Thanks To Roku, These Huge Winners (Investor's Business Daily)
Nov-01-23 07:06AM	Verve Therapeutics (VERV) Surges 28.0%: Is This an Indication of Further Gains? (Zacks)
05:40AM	Inside Cathie Woods Portfolio: 3 Stocks She Is Betting Millions On (InvestorPlace)
Oct-31-23 07:09PM	Why Beam and Verve Therapeutics Shares Soared While Eli Lilly Soured Today (Motley Fool) +27.95%
04:04PM	Verve Stock Soars On $250 Million Eli Lilly Deal (Investor's Business Daily)
06:01AM	Verve and Lilly Relationship Expands to Include Verve's In Vivo Gene Editing Programs Targeting PCSK9 and ANGPTL3 (GlobeNewswire)
05:00AM	Lilly buys out Beam in heart drug alliance with Verve (BioPharma Dive)
Oct-30-23 03:46PM	Top 20 Genomics Companies in the World (Insider Monkey) +6.45%
08:30AM	With 1 Roadblock Down, Is Verve Therapeutics a Buy Now? (Motley Fool)
Oct-25-23 01:45AM	These Gene-Editing Stocks Are Survivors. Take Another Look. (Barrons.com)
Oct-23-23 07:38AM	Verve Surges After FDA Lifts Hold on Gene-Editing Therapy (Bloomberg)
06:30AM	Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia (GlobeNewswire)
Oct-10-23 09:45AM	2 Incredible Growth Stocks Near 52-Week Lows to Buy Now (Motley Fool)
Sep-27-23 07:49AM	Verve Therapeutics (VERV) Soars 13.8%: Is Further Upside Left in the Stock? (Zacks)
Sep-26-23 06:30AM	Verve to Present Interim Data from the heart-1 Phase 1b Clinical Trial of VERVE-101 in HeFH Patients at the American Heart Associations Scientific Sessions 2023 (GlobeNewswire) +13.75%
Sep-21-23 04:05PM	Verve Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference (GlobeNewswire)
Sep-18-23 06:30AM	Verve Expands Leadership Team with Appointment of Frederick T. Fiedorek, M.D., as Chief Medical Officer (GlobeNewswire)
Aug-31-23 10:30AM	1 Cathie Wood Stock That Could Go Parabolic Soon (Motley Fool)
Aug-11-23 09:10AM	Investors in Verve Therapeutics (NASDAQ:VERV) have unfortunately lost 47% over the last year (Simply Wall St.)
Aug-10-23 07:50AM	Verve Therapeutics (VERV) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
06:40AM	Verve Therapeutics: Q2 Earnings Snapshot (AP Finance)
06:30AM	Verve Therapeutics Highlights Recent Company Progress and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-03-23 06:30AM	Verve Therapeutics to Present at the Canaccord 43rd Annual Growth Conference (GlobeNewswire)
Jul-25-23 09:55AM	How Much Upside is Left in Verve Therapeutics (VERV)? Wall Street Analysts Think 93.5% (Zacks)
Jul-13-23 09:53AM	Cathie Wood Is Buying This Biotech, but Here's Why I'm Not (Motley Fool)
Jun-16-23 06:02AM	Verve inks gene-editing deal with Lilly worth up to $525M (American City Business Journals)
Jun-15-23 04:07PM	Eli Lilly Just Lent Its Big Pharma Cachet To Verve's Nascent Gene-Editing Program For $60 Million (Investor's Business Daily) +16.02%
06:30AM	Verve Establishes Global Collaboration with Lilly to Advance Verves In Vivo Gene Editing Program Targeting Lp(a) for the Treatment of Atherosclerotic Cardiovascular Disease (GlobeNewswire)
Jun-09-23 08:02AM	12 Best Short Squeeze Stocks to Buy Now (Insider Monkey)
Jun-01-23 06:30AM	Verve Therapeutics to Participate in the 2023 Jefferies Healthcare Conference (GlobeNewswire)
May-23-23 06:30AM	Verve Therapeutics to Participate in the Stifel 2023 Tailoring Genes: Virtual Genetic Medicines Day (GlobeNewswire)
May-15-23 07:45AM	Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
06:36AM	Verve Therapeutics: Q1 Earnings Snapshot (AP Finance)
06:30AM	Verve Therapeutics Announces Pipeline Progress and Expansion and Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-11-23 07:21AM	We're Not Very Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Rate (Simply Wall St.)
May-09-23 06:30AM	Verve Therapeutics to Participate in the RBC Capital Markets 2023 Global Healthcare Conference (GlobeNewswire) +9.50%
Apr-20-23 06:24PM	Top 10 CRISPR Stocks To Buy (Insider Monkey)
Mar-31-23 12:04PM	Verve Therapeutics, Inc. (NASDAQ:VERV) insider upped their holding by 2.4% earlier this year (Simply Wall St.)
Mar-27-23 06:30AM	Verve Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day (GlobeNewswire)
Mar-04-23 07:32AM	Verve Therapeutics (NASDAQ:VERV) shareholders are up 4.6% this past week, but still in the red over the last year (Simply Wall St.)

Verve Therapeutics, Inc. is a genetic medicines company, which engages in the development of approach to the care of cardiovascular diseases. The company was founded by Burt A. Adelman, Keith J. Joung, Sekar Kathiresan, Kiran Musunuru, Anthony Philippakis, Issi Rozen, and Barry Ticho in 2018 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Nickerson Joan	Chief Administrative Officer	Apr 02 '24	Sale	8.24	1,514	12,475	8,659	Apr 03 05:00 PM
Dorval Allison	Chief Financial Officer	Nov 29 '23	Sale	11.45	554	6,343	4,060	Dec 01 04:30 PM

Open in Screener

PBYI

Puma Biotechnology Inc

May 13 • 04:00PM ET

5.14

Dollar change +0.33
Percentage change 6.76	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

PBYI Puma Biotechnology Inc daily Stock Chart

Held by: VTI VXF AVUV DFAS IWC AVSC FESM EES DFUS SQLV

Index	-	P/E	15.96	EPS (ttm)	0.32	Insider Own	28.05%	Shs Outstand	47.65M	Perf Week	11.15%
Market Cap	247.71M	Forward P/E	21.10	EPS next Y	0.24	Insider Trans	-0.63%	Shs Float	34.71M	Perf Month	-2.56%
Income	15.38M	PEG	-	EPS next Q	-0.05	Inst Own	55.67%	Short Float	8.97%	Perf Quarter	-19.26%
Sales	226.63M	P/S	1.09	EPS this Y	-45.93%	Inst Trans	-2.11%	Short Ratio	5.42	Perf Half Y	55.14%
Book/sh	1.06	P/B	4.86	EPS next Y	0.00%	ROA	7.49%	Short Interest	3.11M	Perf Year	72.90%
Cash/sh	2.22	P/C	2.31	EPS next 5Y	-	ROE	40.02%	52W Range	2.13 - 7.73	Perf YTD	18.59%
Dividend Est.	-	P/FCF	6.98	EPS past 5Y	-	ROI	13.80%	52W High	-33.57%	Beta	1.07
Dividend TTM	-	Quick Ratio	1.38	Sales past 5Y	-0.59%	Gross Margin	73.44%	52W Low	141.08%	ATR (14)	0.30
Dividend Ex-Date	-	Current Ratio	1.46	EPS Y/Y TTM	202.04%	Oper. Margin	11.74%	RSI (14)	52.73	Volatility	4.71% 5.71%
Employees	185	Debt/Eq	2.17	Sales Y/Y TTM	-3.59%	Profit Margin	6.78%	Recom	3.00	Target Price	4.33
Option/Short	Yes / Yes	LT Debt/Eq	1.19	EPS Q/Q	-436.36%	Payout	0.00%	Rel Volume	0.56	Prev Close	4.81
Sales Surprise	-10.70%	EPS Surprise	53.85%	Sales Q/Q	-17.07%	Earnings	May 02 AMC	Avg Volume	573.93K	Price	5.14
SMA20	3.41%	SMA50	-1.25%	SMA200	20.97%	Trades		Volume	321,432	Change	6.76%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-28-21	Upgrade	Citigroup	Neutral → Buy	$11
Jun-25-20	Resumed	BofA/Merrill	Underperform	$9
Oct-08-19	Downgrade	Goldman	Neutral → Sell	$24 → $8
May-10-19	Downgrade	Citigroup	Buy → Neutral	$24
May-10-19	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$57 → $20
Jan-17-19	Initiated	Leerink Partners	Mkt Perform	$21
Jan-03-19	Downgrade	Guggenheim	Buy → Neutral
Nov-19-18	Upgrade	Goldman	Sell → Neutral
Nov-02-18	Downgrade	JP Morgan	Neutral → Underweight
Nov-02-18	Downgrade	BofA/Merrill	Buy → Underperform
Oct-01-18	Initiated	Cantor Fitzgerald	Overweight	$75
Sep-17-18	Initiated	Goldman	Sell	$42
May-11-18	Reiterated	Stifel	Buy	$95 → $87
Nov-10-17	Reiterated	RBC Capital Mkts	Sector Perform	$92 → $108
Nov-10-17	Reiterated	Citigroup	Buy	$156 → $164
Oct-02-17	Reiterated	Stifel	Buy	$110 → $130
Sep-11-17	Reiterated	Credit Suisse	Outperform	$118 → $136
Jul-10-17	Resumed	Leerink Partners	Outperform	$115
Jun-06-17	Reiterated	RBC Capital Mkts	Sector Perform	$60 → $88
May-25-17	Reiterated	RBC Capital Mkts	Sector Perform	$40 → $60

Show Previous Ratings

May-03-24 01:09PM	Puma Biotechnology, Inc. (NASDAQ:PBYI) Q1 2024 Earnings Call Transcript (Insider Monkey)
11:31AM	Puma Biotechnology's (PBYI) Q1 Earnings and Revenues Beat (Zacks)
04:02AM	Puma Biotechnology Inc (PBYI) Q1 2024 Earnings Call Transcript Highlights: A Detailed Review of ... (GuruFocus.com)
May-02-24 09:55PM	PBYI Stock Earnings: Puma Biotechnology Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
06:05PM	Puma Biotech (PBYI) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
05:48PM	Loading…
05:48PM	Puma Biotechnology Inc (PBYI) Reports Q1 Financial Results, Misses Analyst Revenue and EPS Forecasts (GuruFocus.com)
05:12PM	Puma Biotech: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Puma Biotechnology Reports First Quarter Financial Results (Business Wire)
Apr-26-24 11:40AM	What's in Store for Puma Biotechnology (PBYI) in Q1 Earnings? (Zacks)
Apr-25-24 10:02AM	Earnings Preview: Puma Biotech (PBYI) Q1 Earnings Expected to Decline (Zacks)
Apr-18-24 04:15PM	Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results (Business Wire)
Apr-11-24 06:00PM	Puma Biotech (PBYI) Stock Dips While Market Gains: Key Facts (Zacks)
Apr-03-24 05:30PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-22-24 09:25AM	Puma Biotechnology (PBYI) Soars 14.0%: Is Further Upside Left in the Stock? (Zacks)
Mar-20-24 08:30AM	Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer (Business Wire) +9.19%
08:29AM	Loading…
Mar-02-24 08:29AM	Puma Biotechnology, Inc. (NASDAQ:PBYI) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-01-24 09:55AM	Q4 2023 Puma Biotechnology Inc Earnings Call (Thomson Reuters StreetEvents) -5.31%
09:40AM	Why Puma Biotech (PBYI) is a Top Value Stock for the Long-Term (Zacks)
09:39AM	Puma Biotechnology (PBYI) Q4 Earnings & Revenues Lag Estimates (Zacks)
Feb-29-24 04:41PM	Puma Biotechnology Inc (PBYI) Reports Positive Net Income for Q4 and Full Year 2023 (GuruFocus.com) -5.76%
04:40PM	Puma Biotech: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Feb-27-24 06:30PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
11:51AM	Puma Biotechnology (PBYI) to Report Q4 Earnings: What's in Store? (Zacks)
Feb-22-24 04:10PM	Puma Biotechnology to Participate in a Panel Discussion at TD Cowens 44th Annual Health Care Conference (Business Wire) -9.22%
Feb-15-24 04:10PM	Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results (Business Wire) -5.54%
Feb-13-24 08:30AM	Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer (Business Wire)
Jan-31-24 12:58PM	3 Strong Buy Stocks Under $5: January 2024 (InvestorPlace)
Jan-11-24 04:07PM	Puma Biotechnology to Present at B. Riley Securities 4th Annual Oncology Conference (Business Wire)
Jan-06-24 11:02AM	Puma Biotechnology Inc CEO Alan Auerbach Sells 41,396 Shares (GuruFocus.com)
08:30AM	Loading…
Dec-11-23 08:30AM	Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer (Business Wire) -7.99%
Nov-20-23 11:47AM	Here's Why You May Invest in Puma Biotechnology (PBYI) Stock (Zacks)
Nov-06-23 05:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-03-23 12:16PM	Puma Biotech (PBYI) Q3 Earnings Beat, Revenues Lag Estimates (Zacks) +11.65%
09:34AM	Q3 2023 Puma Biotechnology Inc Earnings Call (Thomson Reuters StreetEvents)
09:31AM	Puma Biotechnology, Inc. (NASDAQ:PBYI) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-02-23 07:42PM	Puma Biotechnology Inc (PBYI) Reports Positive Net Income and Cash Flow in Q3 2023 (GuruFocus.com) -6.04%
04:47PM	Puma Biotech: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Puma Biotechnology Reports Third Quarter 2023 Financial Results (Business Wire)
Oct-19-23 04:14PM	Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2023 Financial Results (Business Wire)
Oct-14-23 12:30PM	Puma Biotechnology Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting (Business Wire)
Oct-04-23 05:30PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-22-23 07:57AM	Puma's (PBYI) Alisertib Gets FDA's Orphan Drug Tag for SCLC (Zacks)
Sep-21-23 04:10PM	Puma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the Treatment of Small Cell Lung Cancer (Business Wire)
Aug-31-23 04:07PM	Puma Biotechnology to Present at the H.C. Wainwright 25th Annual Global Investment Conference (Business Wire)
Aug-08-23 08:30AM	Puma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer (Business Wire)
Aug-04-23 12:36PM	Puma Biotech (PBYI) Q2 Earnings Beat, Nerlynx Sales Outperform (Zacks) +8.52%
09:23AM	Q2 2023 Puma Biotechnology Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-03-23 05:17PM	Puma Biotech: Q2 Earnings Snapshot (AP Finance)
04:05PM	Puma Biotechnology Reports Second Quarter Financial Results (Business Wire)
Jul-20-23 04:15PM	Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2023 Financial Results (Business Wire)
Jun-13-23 09:30AM	5 Biotech Stocks to Buy as Industry Prospects for 2H23 Look Good (Zacks)
Jun-06-23 05:03PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-04-23 09:00AM	Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting (Business Wire)
May-28-23 10:06AM	Should You Be Concerned About Puma Biotechnology, Inc.'s (NASDAQ:PBYI) ROE? (Simply Wall St.)
May-22-23 11:07AM	Reasons to Add Puma (PBYI) Stock to Your Portfolio Right Now (Zacks) +5.54%
May-05-23 05:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +20.69%
12:45PM	Puma Biotech (PBYI) Q1 Earnings Beat, Nerlynx Sales Rise Y/Y (Zacks)
09:44AM	Q1 2023 Puma Biotechnology Inc Earnings Call (Thomson Reuters StreetEvents)
May-04-23 05:32PM	Puma Biotech: Q1 Earnings Snapshot (AP Finance)
04:04PM	Puma Biotechnology Reports First Quarter Financial Results (Business Wire)
Apr-20-23 04:15PM	Puma Biotechnology to Host Conference Call to Discuss First Quarter 2023 Financial Results (Business Wire)
Apr-17-23 06:49AM	Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 34% (Simply Wall St.)
Apr-11-23 05:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-14-23 08:30AM	Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology (Business Wire)
Mar-06-23 09:48AM	Puma Biotechnology, Inc. (NASDAQ:PBYI) Q4 2022 Earnings Call Transcript (Insider Monkey) -6.23%
Mar-03-23 05:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -19.35%
02:20PM	Puma Biotech (PBYI) Q4 Loss Wider Than Expected, Sales Top (Zacks)
06:22AM	Q4 2022 Puma Biotechnology Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-02-23 04:05PM	Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results (Business Wire)
Feb-28-23 04:15PM	Puma Biotechnology to Participate in a Panel Discussion at Cowens 43rd Annual Health Care Conference (Business Wire)
Feb-19-23 02:05PM	7 A-Rated Penny Stocks Worth Betting On (InvestorPlace)
Feb-16-23 04:31PM	Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results (Business Wire)
Feb-07-23 05:30PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.31%
Feb-01-23 08:30AM	Puma Biotechnologys NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Breast Cancer with a HER2 Mutation (Business Wire)
Jan-25-23 06:19AM	Puma Biotechnology's (NASDAQ:PBYI) investors will be pleased with their decent 96% return over the last year (Simply Wall St.)
Jan-12-23 04:15PM	Puma Biotechnology to Present at B. Riley Securities 3rd Annual Oncology Conference (Business Wire)
Jan-11-23 05:30PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-09-23 08:55AM	Puma Biotechnology Releases Updated Corporate Presentation (Business Wire)
Dec-20-22 08:31AM	Institutional investors own a significant stake of 45% in Puma Biotechnology, Inc. (NASDAQ:PBYI) (Simply Wall St.)
Dec-15-22 03:39PM	Why Shares of Puma Biotechnology Rose This Week (Motley Fool)
Dec-07-22 06:03PM	Puma Biotechnology Presents Updated Findings from the TBCRC-022 Trial at the 2022 San Antonio Breast Cancer Symposium (Business Wire)
Dec-05-22 05:30PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-01-22 08:36AM	15 Best Affordable Stocks Under $30 (Insider Monkey)
Nov-28-22 09:55AM	Puma Biotech (PBYI)'s Technical Outlook is Bright After Key Golden Cross (Zacks)
Nov-22-22 09:15AM	Puma Biotechnology, Inc. (PBYI) Hits Fresh High: Is There Still Room to Run? (Zacks)
08:50AM	Is Puma Biotechnology (PBYI) Stock a Solid Choice Right Now? (Zacks)
Nov-21-22 05:25PM	Why Puma Biotechnology's Shares Jumped 20% on Monday (Motley Fool) +20.00%
Nov-17-22 09:40AM	Is Biogen (BIIB) a Great Value Stock Right Now? (Zacks) +12.74%
Nov-14-22 10:10AM	Bayer (BAYRY) Eylea Label Extension Gets CHMP Positive Opinion (Zacks) +13.52%
09:50AM	Why Puma Biotech (PBYI) is a Top Momentum Stock for the Long-Term (Zacks)
Nov-11-22 10:20AM	Viatris (VTRS) Wins in Court Against AstraZeneca's Symbicort (Zacks)
Nov-09-22 10:43AM	Regeneron (REGN) Gets FDA Nod for Libtayo's Label Expansion (Zacks) -9.51%
06:02AM	Puma Biotechnology Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.)
Nov-07-22 01:02PM	Why Puma Biotechnology, Inc. (NASDAQ:PBYI) Looks Like A Quality Company (Simply Wall St.) +15.50%
Nov-04-22 12:29PM	Intra-Cellular (ITCI) Beat on Q3 Earnings and Sales Estimates (Zacks) +26.64%
12:20PM	Agios (AGIO) Q3 Loss Narrower Than Expected, Sales Miss (Zacks)
12:18PM	Intellia's (NTLA) Q3 Loss Wider Than Expected, Revenues Up Y/Y (Zacks)
11:18AM	Puma Biotech (PBYI) Q3 Earnings Top, Nerlynx Sales View Up (Zacks)
Nov-03-22 06:45PM	Puma Biotech (PBYI) Reports Q3 Loss, Tops Revenue Estimates (Zacks)

Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
AUERBACH ALAN H	President and CEO	Jan 03 '24	Sale	4.49	41,396	185,698	6,936,947	Jan 05 06:56 PM
NOUGUES MAXIMO F	Chief Financial Officer	Jan 03 '24	Sale	4.49	15,682	70,348	128,666	Jan 05 06:49 PM
Ludwig Jeffrey Jerome	Chief Commercial Officer	Jan 03 '24	Sale	4.49	12,956	58,119	99,970	Jan 05 07:00 PM
HUNT DOUGLAS M	See Remarks	Jan 03 '24	Sale	4.49	8,358	37,493	103,319	Jan 05 06:42 PM
Wong Alvin F	Chief Scientific Officer	Jan 03 '24	Sale	4.49	7,733	34,689	98,214	Jan 05 07:03 PM
Wong Alvin F	Chief Scientific Officer	Dec 04 '23	Sale	3.76	280	1,053	97,934	Jan 10 04:41 PM
MILLER MICHAEL PATRICK	Director	Nov 07 '23	Sale	2.83	25,000	70,802	43,358	Nov 09 04:19 PM
AUERBACH ALAN H	President and CEO	Jul 03 '23	Sale	3.31	60,698	200,983	6,978,343	Jul 06 07:03 PM
NOUGUES MAXIMO F	Chief Financial Officer	Jul 03 '23	Sale	3.31	14,680	48,608	144,348	Jul 06 07:12 PM
Ludwig Jeffrey Jerome	Chief Commercial Officer	Jul 03 '23	Sale	3.31	12,103	40,075	112,926	Jul 06 07:08 PM
HUNT DOUGLAS M	See Remarks	Jul 03 '23	Sale	3.31	7,809	25,857	111,677	Jul 06 07:06 PM
Wong Alvin F	Chief Scientific Officer	Jul 03 '23	Sale	3.31	6,938	22,973	105,947	Jul 06 07:16 PM
Senderowicz Adrian	Director	Jun 13 '23	Sale	3.45	27,000	93,280	0	Jun 15 09:03 PM
WILSON TROY EDWARD	Director	Jun 13 '23	Sale	3.45	27,000	93,269	350	Jun 15 09:14 PM
MOYES JAY M	Director	Jun 13 '23	Sale	3.45	22,000	75,970	16,322	Jun 15 09:10 PM
MILLER MICHAEL PATRICK	Director	Jun 13 '23	Sale	3.45	13,500	46,630	41,358	Jun 15 08:28 PM
Dorval Allison	Director	Jun 13 '23	Sale	3.45	10,000	34,500	17,000	Jun 15 09:01 PM
Stuglik Brian M	Director	Jun 13 '23	Sale	3.46	9,900	34,252	31,958	Jun 15 09:06 PM
Wong Alvin F	Chief Scientific Officer	Jun 02 '23	Sale	3.45	269	928	112,885	Jun 06 04:36 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

VERV

Verve Therapeutics Inc

PBYI

Puma Biotechnology Inc

Upgrade your FINVIZ experience